Date: 2015-11-24
Type of information: R&D agreement
Compound: improved version (biobettter) of teriparatide
Company: Novozymes (Denmark) Paras Biopharmaceuticals (Finland)
Therapeutic area: Bone diseases
Type agreement: R&D
Action mechanism: peptide/parathyroid hormone related peptide. Parathyroid hormone (PTH) is the primary regulator of calcium and phosphate metabolism in bone and kidney.Teriparatide is an active fragment of PTH. Its actions include stimulation of bone formation by direct effects on osteoblasts indirectly increasing the intestinal absorption of calcium and increasing the tubular re-absorption of calcium and excretion of phosphate by the kidney.
Disease: osteoporosis
Details: * On November 24, 2015, Novozymes Biopharma and Paras Biopharmaceuticals announced that they will collaborate to generate an improved version – a biobetter - of teriparatide, a leading treatment for osteoporosis. The partners will apply Novozymes’ VELTIS technology and Paras Biopharmaceuticals’ Diabrid NobleCleav technology to create a superior osteoporosis medicine. Already well-established in the fields of diabetes, hemophilia and neutropenia, the VELTIS platform provides once-weekly, once bi-weekly or once-monthly peptide or protein dosing. As a result, VELTIS offers the potential for enhanced patient adherence and improved therapeutic impact
Financial terms:
Latest news:
